New Study Finds Impella® Heart Pump Reduces Injury to Kidneys During High-Risk Percutaneous Coronary Intervention

March 9, 2017

Specialist Opinion with Dr. Seth Bilazarian

A new retrospective, single-center study published in Circulation Research finds use of hemodynamic support with Impella 2.5® heart pump during high-risk percutaneous coronary intervention (HRPCI) can reduce the risk of acute kidney injury (AKI) even when those patients had preexisting kidney disease and low ejection fraction (EF). The new study builds upon earlier data from PROTECT II2, a randomized clinical trial, which found kidney injury rates were numerically lower when more contrast was used during HRPCI, and adds to the growing body of evidence of the benefits of hemodynamic support with Impella during HRPCI.

Tune in as Dr. Seth Bilazarian summarizes the study and puts the study into context.

 Learn more:

  1. Flaherty MP, Pant S, Patel SV, et al. Hemodynamic Support with a Micro-Axial Percutaneous Left Ventricular Assist Device (Impella®) Protects Against Acute Kidney Injury in Patients Undergoing High-Risk Percutaneous Coronary Intervention. Circ Res. 2017 Jan 10.
  2. O'Neill WW, Kleiman NS, Moses J, et al. A prospective, randomized clinical trial of hemodynamic support with Impella 2.5 versus intra-aortic balloon pump in patients undergoing high-risk percutaneous coronary intervention: the PROTECT II study. Circulation. 2012 Oct 2;126(14):1717-27.

NPS-014-17


To learn more about the Impella® platform of heart pumps, including important risk and safety information associated with the use of the devices, please visit: www.protectedpci.com/indications-use-safety-information/